Vitamin D deficiency is significantly associated with depression in patients with chronic kidney disease by 媛뺤떊�슧 et al.
RESEARCH ARTICLE
Vitamin D deficiency is significantly associated
with depression in patients with chronic
kidney disease
Jong Hyun Jhee1, Hyoungnae Kim1, Seohyun Park1, Hae-Ryong Yun1, Su-Young Jung1,
Youn Kyung Kee1, Chang-Yun Yoon1, Jung Tak Park1, Seung Hyeok Han1, Shin-
Wook Kang1,2, Tae-Hyun Yoo1*
1 Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei
University, Seoul, Korea, 2 Department of Internal Medicine, College of Medicine, Severance Biomedical
Science Institute, Brain Korea 21 PLUS, Yonsei University, Seoul, Korea
* yoosy0316@yuhs.ac
Abstract
Background
Depression is reported to be the most common psychological problem in patients with
chronic kidney disease (CKD). Several studies have reported that lower levels of serum vita-
min D are significantly associated with depression. Both vitamin D deficiency and depres-
sion are prevalent in patients with CKD, yet the relationship between these two factors
remains poorly understood. This study aimed to investigate the association between vitamin
D levels and depression among CKD patients.
Methods
Totally, 21,257 individuals who participated in the Korean National Health and Nutrition
Examination Survey (KNHANES V, VI) from 2010–2014 were screened for the study; 533
CKD patients were included. Vitamin D deficiency was defined as serum 25-hydroxyvitamin
D3 [25(OH)D3]10 ng/mL. Patients were divided into vitamin D deficient or sufficient
groups. Depression was screened for using the Korean version of the WHO Composite
International Diagnostic Interview-Short Form. The association between vitamin D defi-
ciency and depression was evaluated by multivariate logistic regression analysis.
Results
The mean participant age was 70.1±9.4 years; 262 patients (49.2%) were male. The median
25(OH)D3 level was 19.1±6.9 ng/mL. The prevalence of depression was higher in CKD
patients than in the general population (14.3 vs. 11.1%, P = 0.03). Additionally, the preva-
lence of depression was significantly higher in CKD patients with (vs. without) vitamin D defi-
ciency (32.5% vs. 50.0%, P<0.001). Multivariate logistic regression analysis showed that
vitamin D deficiency was a significant independent predictor of depression after adjusting
for confounding factors (adjusted odds ratio, 6.15; 95% confidence interval, 2.02–8.75;
P = 0.001).
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Conclusion
Depression was highly prevalent in CKD patients, in whom vitamin D deficiency was a signif-
icant independent predictor of depression. Therefore, management of vitamin D deficiency
might help prevent depression in CKD patients.
Introduction
Depression is reported to be the most common psychological problem in patients with chronic
kidney disease (CKD) [1,2]. The prevalence of depression in patients with CKD is approxi-
mately 20–30%, which is higher than that of other chronic diseases [3,4]. Depression may
result in poor quality of life and functional impairment, and may also hinder adherence to
medical treatment and impair nutritional status [5,6]. Accumulating evidence has shown that
depressive symptoms in patients undergoing dialysis are independent predictors of adverse
clinical outcomes. The Dialysis Outcomes and Practice Patterns Study (DOPPS) showed a sig-
nificant association between both mortality and hospitalization rates and depressive symptoms
[7]. Moreover, high levels of depressive symptoms are found to be correlated with increased
risk of cardiovascular events in an analysis from the Choices for Healthy Outcomes in Caring
for End-Stage Renal Disease (CHOICE) study [8]. Recently, prospective studies found that
patients with pre-dialysis CKD who experienced episodes of major depression were more
likely to progress to dialysis [9,10].
Serum 25-hydroxyvitamin D3 [25(OH)D3] levels begin to decrease in stage 2 CKD
[11,12], and deficiency of serum 25(OH)D3 is present in all subsequent stages of CKD [13–
17], including end-stage renal disease (ESRD). Proteinuria may be accompanied by high
urinary loss of vitamin D-binding protein, leading to increased renal loss of vitamin D
metabolites [14,18,19]. Low serum 25(OH)D3 levels in patients with CKD have been associ-
ated with a higher risk of all-cause mortality and faster progression of kidney disease [20–
22]. In the Third National Health and Nutrition Examination Survey (NHANES III) cohort
[13], individuals with 25(OH)D3 levels lower than 15 ng/mL had a higher risk for all-cause
mortality despite adjustments for CKD stage and confounding factors. Such findings have
led to investigate on the role of 25(OH)D3 in multiple chronic diseases [23,24], and increase
in serologic testing and use of vitamin D supplementation [25,26]. Various population and
clinical research has implicated vitamin D deficiency as a potential risk factor for several
chronic diseases, including hypertension, obesity, diabetes, cardiovascular diseases, autoim-
mune diseases, as well as depression [27–33]. Therefore, adequate vitamin D levels are a
therapeutic goal for patients with kidney disease, in order to prevent several complications
[34].
Several studies have reported that lower levels of serum 25(OH)D3 are significantly associ-
ated with depression [35–38]. Schneider et al. [39] suggested that psychiatric disorders, espe-
cially depression, may be associated with low levels of serum 25(OH)D3. Underlying causes of
vitamin D deficiency, such as less sun exposure, can result from decreased outdoor physical
activity, different housing or clothing habits, and decreased vitamin supplementation [40].
However, depression may also be a consequence of vitamin D deficiency. Serum 25(OH)D3
deficiency, while common, is highly treatable, which may help prevent depression.
As mentioned above, recent studies have reported the association between vitamin D defi-
ciency and depression in the general population. Even though both vitamin D deficiency and
depression are prevalent in patients with CKD, the relationship between these two factors
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remains poorly elucidated. Therefore, this study aimed to investigate the association between
vitamin D levels and depression among patients with CKD.
Methods
Study design, setting, and participants
This study was based on data from the fifth and sixth editions of Korean National Health and
Nutrition Examination Survey (KNHANES V, VI, 2010–2014, S1 Data). The KNHANES is a
cross-sectional survey conducted periodically to assess the Korean public health and nutri-
tional status. The KNHANES is composed of demographic, anthropometric, nutritional, and
personal medical history data collected by trained investigators. Sampling frame was devel-
oped based on the multistage probability sampling that was stratified according to geographic
location, gender, and age. In the fifth and sixth KNHANES (2010–2014), a total of 41,102 indi-
viduals aged 1 year were sampled. Among them, 21,257 individuals were screened for this
study. Of the screened individuals, we only performed analyses of adults aged 19 years (Fig
1). We excluded individuals whose data were missing for important analytic variables, such as
serum 25(OH)D3 levels, serum creatinine, and the mental health questionnaire. CKD was
defined as an estimated glomerular filtration rate (eGFR) lower than 60 mL/min/1.73 m2 with
or without proteinuria. Finally, 533 individuals who met the definition of CKD were included
in the statistical analysis. The KNHANES was approved by the Institutional Review Board of
the Centers for Disease Control and Prevention in Korea. All participants of the KNHANES
used in this study provided their written informed consent.
General characteristics of study participants
Anthropometric measurements were acquired by trained investigators following standardized
protocols. Body mass index (BMI) was calculated as weight (kg)/squared height (m2). Demo-
graphic variables that were expected to be confounding factors included age, sex, marital sta-
tus, occupational status, education status, economic status, alcohol behavior, smoking status,
and EuroQol five dimensions (EQ5D) index score. Marital status was divided into two groups
(single or married) based on questionnaire responses. Occupational status was divided into
two groups: employed or unemployed. Education level was divided into three groups: elemen-
tary school, middle–high school, or college. Economic status was divided into three groups
according to monthly income: low, middle, or high. The EQ5D descriptive system had five
dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. A
multi-attribute value function was used to map preferences for each of these health states.
From this scoring algorithm, EQ5D index scores were calculated based on subjects’ responses
to the five-item questionnaire. Scoring algorithm for the EQ5D index used in this study was
based on the Korean value set [41].
Mental health. Mental health data were obtained by means of a self-reported mental
health questionnaire, under the supervision of a trained investigator. Depressive symptoms
were assessed by the following question: “In the past year, have you felt extreme sorrow or
despair for more than two weeks?” Participants answered either “yes” or “no” to this question.
This questionnaire had been used to identify people with depressive mood from the outset of
KNHANES (1998) [42]. It is still widely used to measure participants with either clinical or
subclinical depressive symptoms, which are expected to be substitutes for depressive disorders.
In addition, participants were asked whether they had been diagnosed with depression by a
physician. If subjects answered that they were either experiencing depressive symptoms or
were currently diagnosed with depression, they were defined as having depression. Finally,
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participants were divided into two groups according to their answer, ‘‘depressive” or ‘‘non-
depressive” group.
Serum 25(OH)D3 assessment and laboratory data. Blood samples, collected from the
antecubital vein after a 10 to 12 hour fast, were used to assess serum levels of biochemical
markers. Serum levels of 25(OH)D3 were measured by gamma counter with a radioimmuno-
assay (25-hydroxy-vitamin D125 I RIA Kit; DiaSorin, Stillwater, MN, USA) using a 1470 Wiz-
ard Gamma Counter (PerkinElmer, Turku, Finland). To make an effort for minimizing the
analytical variation, serum 25(OH)D3 levels were analyzed by the same institute, which carried
out a quality assurance program throughout the analysis period. Inter-assay coefficients of var-
iation were 1.9–6.1% for the samples [43]. Participants were divided into two groups according
to serum 25(OH)D3 levels: 25(OH)D3 deficient group ( 10 ng/mL) and 25(OH)D3 sufficient
group (>10 ng/mL) [44]. In addition, biochemical laboratory test results for the following fac-
tors were collected: serum hemoglobin, glucose, total cholesterol, and glycosylated hemoglobin
(Hba1c). Proteinuria was determined semi-quantitatively with a single spot urine dipstick
analysis and reported as negative, trace, 1+, 2+, 3+, or 4+. Proteinuria was defined as 1+ or
higher. The four-variable Modification of Diet in Renal Disease Study equation was used to
calculate the eGFR [45].
Statistical analysis. All statistical analyses were performed using SPSS for Windows ver-
sion 21.0 (SPSS Inc., Chicago, USA). Continuous variables were expressed as the
mean ± standard deviation, and categorical variables as absolute number with percentages.
Each variable was tested for normality before statistical analysis. Comparisons between the
groups were made by the type of analysis for variance or Student’s t-test for continuous vari-
ables and by the chi-squared test or Fisher’s exact test for categorical variables. The Kolmogo-
rov–Smirnov test was performed to determine the normality of the distribution of parameters.
If the resulting data did not show a normal distribution, geometric mean ± standard deviation
was reported; Either Mann–Whitney U test or Kruskal-Wallis test was used for multiple com-
parisons. Logistic regression analysis was done to evaluate the association between depressive
Fig 1. Flow diagram of study participant selection.
doi:10.1371/journal.pone.0171009.g001
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symptom and serum 25(OH)D3 concentration. Odds ratios (ORs) for depressive symptoms
were compared between 25(OH)D3 deficiency group and 25(OH)D3 sufficiency group. Multi-
ple models were constructed for logistic regression. One was analyzed without adjustment,
and others were adjusted for confounding factors including age, sex, smoking status, alcohol
status, BMI, suicidal ideation, EQ5D index, past history of hypertension, diabetes mellitus,
eGFR, proteinuria, serum glucose, hemoglobin, and total cholesterol level. P values less than
0.05 were considered statistically significant.
Results
Baseline characteristics of CKD patients according to 25(OH)D3 level
The baseline characteristics of study participants are shown in Table 1. The mean age was
70.1 ± 9.4 years, and 262 (49.2%) patients were male. The mean 25(OH)D3 level was 19.1 ± 6.9
ng/mL overall, 8.5 ± 1.3 ng/mL in the vitamin D deficient group, and 19.9 ± 6.5 ng/mL in the
sufficient group. The vitamin D deficient group had a greater proportion of female and unem-
ployed patients, and the EQ5D index that represents quality of life was lower. A past history of
diabetes was prevalent in the vitamin D deficient group and the serum hemoglobin level was
lower in the vitamin D deficient group. However, there were no differences in proteinuria,
eGFR, or BMI between the two groups.
Comparison of prevalence of depression between the general
population and CKD patients
Chi-square analysis was performed to compare the prevalence of depression between CKD
patients and the general population (Fig 2A). The prevalence of depression was significantly
higher in CKD patients compared with the general population (24.4% versus 33.8%, P< 0.001).
Comparison of prevalence of depression between the vitamin D deficient
and sufficient groups of CKD patients
We further evaluated the association of depression and vitamin D deficiency in CKD patients.
The prevalence of depression was significantly higher in the vitamin D deficient group of
CKD patients, compared with those with sufficient levels of vitamin D (32.5% versus 50.0%,
P< 0.001, Fig 2B).
Vitamin D deficiency as a predictor of depression in CKD patients
Logistic regression analysis was performed to investigate the independent association between
vitamin D deficiency and depression (Table 2). In the crude logistic regression analysis, vita-
min D deficiency was significantly associated with depression [OR, 2.08; 95% confidence inter-
val (CI), 1.09–3.98; P = 0.03]. In the multivariate logistic regression analysis, the significant
association remained, even after adjustment for factors reported to be associated with depres-
sion, such as age, sex, alcohol status, smoking status, suicidal ideation, occupational status,
education status, economic status, EQ5D index, past history of hypertension or diabetes,
serum hemoglobin level, eGFR, proteinuria, and body mass index (OR, 6.15; 95% CI, 2.02–
18.75; P = 0.001).
Subgroup analysis
Subgroup analysis was conducted according to age, sex, EQ5D index, and presence of diabetes
(Table 3). In the group aged< 65 years, vitamin D deficiency and depression were significantly
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Table 1. Baseline characteristics of CKD patients.
Total (n = 533) Vit D Def (n = 27) Vit D Suf (n = 483) P
Age (years) 70.1 ± 9.4 71.6 ± 10.3 69.9 ± 9.4 0.30
Male (%) 262 (49.2) 13 (32.5) 249 (50.5) 0.03
BMI (kg/m2) 24.6 ± 3.4 24.2 ± 4.8 24.7 ± 3.3 0.36
Smoker (%) 256 (48.0) 14 (35.0) 242 (49.1) 0.09
Alcohol user (%) 260 (65.8) 15 (62.5) 245 (66.0) 0.73
Mental health status:
Suicidal ideation (%) 104 (19.5) 8 (20.0) 96 (19.5) 0.9
Depressive symptom (%) 180 (33.8) 20 (50.0) 160 (32.5) 0.02
EQ5D index 0.84 ± 0.19 0.79 ± 0.21 0.85 ± 0.01 0.10
Stress (%): 0.23
None 151 (28.9) 14 (36.8) 137 (28.3)
Mild 276 (52.9) 15 (39.5) 261 (53.9)
Moderate to severe 95 (18.2) 9 (23.7) 86 (17.8)
Sleeping hours (%) 0.07
< 6 hours 31 (6.1) 5 (12.8) 26 (5.5)
6–9 hours 334 (65.7) 20 (51.3) 314 (67.0)
>10 hours 143 (28.1) 14 (35.9) 129 (27.5)
Socioeconomic status (%):
Married 527 (99.1) 39 (97.5) 488 (99.2)
Economic status 0.23
Low 129 (24.6) 11 (28.9) 118 (24.2)
Middle 258 (49.1) 19 (50.0) 239 (49.1)
High 138 (26.3) 8 (21.1) 130 (26.7)
Education 0.9
 Elementary 292 (56.2) 22 (57.9) 270 (56.0)
Middle-high school 187 (36.0) 13 (34.2) 174 (36.1)
 College 41 (7.9) 3 (7.9) 38 (7.9)
Employed 169 (32.6) 4 (10.5) 165 (34.3) 0.003
Comorbidities (%):
HTN 379 (71.1) 27 (67.5) 352 (71.4) 0.60
DM 168 (31.5) 22 (55.0) 146 (29.6) 0.001
CVD 102 (19.1) 7 (17.5) 95 (19.3) 0.78
Dyslipidemia 145 (27.2) 12 (30.0) 133 (27.0) 0.68
Laboratory data:
Hemoglobin (g/dl) 13.2 ± 1.8 12.3 ± 1.6 13.2 ± 1.8 0.002
eGFR (ml/min/1.73 m2) 50.5 ± 9.8 48.7 ± 11.2 50.6 ± 9.7 0.24
Proteinuria (%) 52 (9.8) 5 (12.5) 47 (9.5) 0.54
Total cholesterol (mg/dl) 186.2 ± 41.3 176.6 ± 39.3 187.0 ± 41.4 0.13
Glucose (mg/dl) 108.9 ± 30.4 109.7 ± 30.1 108.8 ± 30.5 0.87
25(OH)D3 (ng/ml) 19.1 ± 6.9 8.5 ± 1.3 19.9 ± 6.5 <0.001
Data are presented as mean ± SD or n (%).
Abbreviations: Vit D Def, vitamin D deficiency; Vit D Suf, vitamin D sufficiency; CKD, chronic kidney disease; BMI, body mass index; HTN, hypertension;
DM, diabetes mellitus; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate
doi:10.1371/journal.pone.0171009.t001
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associated after adjustment for confounding factors (OR = 398.57; 95% CI: 10.68–14867.71;
P = 0.001). After adjusting for confounding factors, vitamin D deficiency and depression were
significantly associated in female (OR, 42.89; 95% CI, 5.22–352.35; P< 0.001) but not in male
(OR, 0.58; 95% CI, 0.05–6.25; P = 0.65). The patients were divided into two groups according
to EQ5D index. In the higher EQ5D index group, the association between vitamin D defi-
ciency and depression was significant, even after adjustment for confounding variables (OR,
7.49; 95% CI, 1.41–39.74; P = 0.02), whereas in lower EQ5D index group, there was no signifi-
cant association (OR, 3.91; 95% CI, 0.68–22.63; P = 0.13). Patients with no history of diabetes
showed similar results to those above (OR, 18.94; 95% CI, 3.41–105.03; P = 0.001).
Fig 2. (A) Prevalence of depression between the general population and CKD patients (B) Prevalence
of depression between vitamin D deficient and sufficient group among CKD patients.
doi:10.1371/journal.pone.0171009.g002
Vitamin D deficiency and depression in chronic kidney disease
PLOS ONE | DOI:10.1371/journal.pone.0171009 February 13, 2017 7 / 13
Discussion
This study showed that vitamin D deficiency was significantly associated with depressive
symptoms in patients with CKD. Consistent with previous reports, the prevalence of depres-
sion was significantly higher in these individuals compared with the general population.
Table 2. Logistic regression analysis for the prevalence of depression with adjustment for various factors.
Crudea Model 1b Model 2c Model 3d
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Vit. D deficiency 2.08 (1.09–3.98) 0.03 5.13 (1.81–4.52) 0.002 5.02 (1.75–14.42) 0.003 6.15 (2.02–8.75) 0.001
Age 0.97 (0.93–1.01) 0.14 0.97 (0.93–5.75) 0.15 0.97 (0.93–1.01) 0.14
Male 1.68 (0.50–5.59) 0.40 1.65 (0.49–5.58) 0.42 1.35 (0.37–4.10) 0.65
Smoking status 1.71 (0.34–3.38) 0.9 1.05 (0.33–3.36) 0.9 1.01 (0.31–3.26) 0.9
Alcohol behavior 0.89 (0.43–1.82) 0.74 0.89 (0.43–1.84) 0.76 0.83 (0.39–1.74) 0.62
Occupation 1.06 (0.47–2.40) 0.89 1.07 (0.47–2.42) 0.88 1.08 (0.47–2.48) 0.85
Economic status 0.94 (0.56–1.59) 0.81 0.94 (0.56–1.59) 0.82 0.93 (0.55–1.58) 0.79
Education status 1.32 (0.71–2.46) 0.37 1.32 (0.71–2.45) 0.38 1.40 (0.74–2.64) 0.30
Suicidal ideation NA 0.9 NA 0.9 NA 0.9
EQ5D index 0.94 (0.92–0.96) <0.001 0.94 (0.92–0.96) <0.001 0.94 (0.92–0.96) <0.001
HTN 0.98 (0.46–2.06) 0.9 0.91 (0.42–2.01) 0.82
DM 1.09 (0.52–2.28) 0.81 1.00 (0.46–2.17) 0.9
eGFR 0.99 (0.96–1.03) 0.71
Proteinuria 0.45 (0.13–1.63) 0.23
Hemoglobin 0.94 (0.73–1.20) 0.56
BMI 1.08 (0.96–1.21) 0.20
a Unadjusted model
b Adjusted for age, sex, alcohol, smoking, suicidal idea, and EQ5D index
c Adjusted for Model 1 + HTN and DM
d Adjusted for Model 2 + hemoglobin, glucose, total cholesterol, eGFR, proteinuria, and BMI
Abbreviations: OR, odds ratio; CI, confidence interval; Vit. D, vitamin D; NA, not applicable; HTN, hypertension; DM, diabetes mellitus; eGFR, estimated
glomerular filtration rate; BMI, body mass index
doi:10.1371/journal.pone.0171009.t002
Table 3. Subgroup analysis according to age, sex, EQ5D index, and presence of diabetes with multiple logistic regression analysis for the pres-
ence of depression.
Subgroup Variable OR (95% CI) P
Age
< 65 Vitamin D deficiency 398.57 (10.68–14867.71) 0.001
 65 Vitamin D deficiency 2.23 (0.49–10.01) 0.30
Sex
Female Vitamin D deficiency 42.88 (5.22–352.35) <0.001
Male Vitamin D deficiency 0.58 (0.05–6.25) 0.65
EQ5D index a
High Vitamin D deficiency 7.49 (1.41–39.74) 0.02
Low Vitamin D deficiency 3.91 (0.67–22.63) 0.13
Diabetes mellitus
No Vitamin D deficiency 18.94 (3.41–105.03) 0.001
Yes Vitamin D deficiency 5.00 (0.76–32.84) 0.09
a Subgroup was divided according to EQ5D index. The mean values of EQ5D index were 0.98 and 0.71 in the high and low groups, respectively.
doi:10.1371/journal.pone.0171009.t003
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Among patients with CKD, depression was more prevalent in the vitamin D deficiency group.
Furthermore, vitamin D deficiency was an independent predictor of depression in patients
with CKD, even after adjustment for confounders. To the best of our knowledge, this is the
first investigation elucidating a relationship between vitamin D deficiency and depressive
symptoms in patients with CKD.
In this study, the prevalence of depression in CKD subjects was significantly higher com-
pared with the general population. Furthermore, this study showed that vitamin D deficiency
was an independent predictor for the presence of depression even after adjustment for multi-
ple confounding factors in CKD patients. Although the cause of depression in patients with
CKD is multifactorial, vitamin D deficiency is one of the plausible factors that has recently gar-
nered much interest [46]. Vitamin D is a distinctive neurosteroid hormone and may play an
important role in the development of depression. Vitamin D receptors are present extensively
on neurons and glia in many areas of the brain, including the cingulate cortex and hippocam-
pus, which have been implicated in the pathophysiology of depression [47]. Vitamin D also
promotes the synthesis of depression-related monoamine neurotransmitters, such as seroto-
nin, and is involved in numerous brain processes, including neuroimmuno-modulation, regu-
lation of neurotrophic factors, neuroprotection, neuroplasticity, and brain development,
making it biologically reasonable that vitamin D deficiency might contribute to the develop-
ment of depression [48,49]. In addition, regarding physical functioning, vitamin D receptors
have been observed in the cerebellum, which is an important area of the brain for mobility,
gait, and balance [47], and in muscle tissue, which facilitates muscle contraction speed,
muscle power, and cell growth [48]. Vitamin D deficiency might attenuate muscle power and
further lead to poor physical functioning. It is well known that reduced physical activity is a
risk factor for depression [50]. For reasons mentioned above, vitamin D deficiency can lead to
depression.
Several risk factors for vitamin D deficiency have been identified, some of which are also
associated with depression. These include aging, female sex, dark skin pigmentation, winter
season, obesity, impaired liver function, no use of vitamin D supplements, antidepressant and
anticonvulsant medication use, and psychiatric comorbidities such as anxiety or eating disor-
ders [51]. Furthermore, a range of medical conditions, including cardiovascular, liver, and
renal disease may be associated with low vitamin D levels [52]. However, to date, even though
both vitamin D deficiency and depression are prevalent in patients with CKD, the relationship
between these two factors in this group of patients has been poorly elucidated. In this regard,
this study is notable in that it is the first to investigate the association between vitamin D defi-
ciency and depression in CKD patients. In this study, CKD patients with low vitamin D levels
were older, more likely to have diabetes, and had lower levels of hemoglobin. These factors
are known to be markers of poor medical condition. This poor state of health can be one of
the risk factors for depressive symptoms. Thus, poor medical condition in the group with vita-
min D deficiency could be a reason for the relationship between vitamin D deficiency and
depression.
It is well known that the blood level of vitamin D in patients with CKD is low [53]. Limited
exposure to sunlight in combination with impaired UVB-induced vitamin D synthesis in the
skin and disturbed vitamin D metabolism are considered to contribute to low 25(OH)D3 levels
in patients with CKD [54,55]. As previously mentioned, vitamin D deficiency is a plausible
risk factor for depressive symptoms. According to the results of the present work, the mean
serum 25(OH)D3 level was 19.1 ng/mL in CKD patients. Hence, almost all CKD patients in
this study experienced vitamin D insufficiency. Thus, this study showed that in patients with
CKD, the prevalence of depressive symptoms is high and, given that vitamin D deficiency
in these patients is highly prevalent [53], management of vitamin D deficiency in CKD is
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beneficial to prevent the development of depression. A randomized double blind trial reported
that supplementation of vitamin D ameliorates depressive symptoms [56]. This result indicates
that vitamin D deficiency is associated with depressive symptoms. However, to date, there is
no randomized control trial targeting CKD patients investigating the relationship between
vitamin D supplementation and depression. Further studies are needed to support the associa-
tion of vitamin D deficiency and depression. Specifically, subgroup analysis revealed that the
strength of associations still had significance in those aged<65 years, in women, in those with
no history of diabetes, and the group whose EQ5D index was high. However, among those
aged 65, with diabetes, or with a low EQ5D index, no association with vitamin D deficiency
and depression was demonstrated. This is likely because patients who are older, have a poor
medical condition, or have a low EQ5D index have a more complicated condition so that
other confounding factors influence the development of depression. However, our results
could be generalizable to CKD patients who are young, female, and have less complicated
medical disease. Among these patients, screening for vitamin D deficiency might prevent
depression.
This study has several limitations. First, as serum vitamin D level is generally affected by the
extent of sun exposure, seasonal variation should be considered. However, because the data
used in this study could not be linked to specific dates of laboratory measure, seasonal varia-
tion could not be included. Second, since the liver is a key organ involved in the metabolism of
vitamin D, a history of liver disease may affect vitamin D deficiency. However, in this study,
only a few subjects had liver disease; hence, we did not adjust for this. Third, serum PTH level
is associated with vitamin D deficiency and depression. Furthermore, it is well-known that
active vitamin D metabolite is more significant in CKD patients. However, since KNHANES
focused on the basic public nutritional status, it does not provide special laboratory findings
such as PTH level and active vitamin D metabolite. Finally, there is paucity of data from ran-
domized control studies on whether supplementation of vitamin D can improve or prevent
depression or adverse clinical outcomes. Further randomized control trials should be per-
formed to determine whether vitamin D supplementation could be beneficial to improve
depression and adverse clinical outcomes in patients with CKD as well as in the general
population.
In conclusion, it is notable that this study demonstrated the association between vitamin D
deficiency and depression in CKD patients. Further randomized control trials should be per-
formed to determine whether vitamin D supplementation could be beneficial to improve
depression and adverse clinical outcomes in CKD patients as well as in the general population.
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